Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a poor prognosis. Pirfenidone is the first antifibrotic agent to be approved for IPF-treatment as it is able to slow down disease progression. However, there is no curative treatment other than lung transplantation. B...

Descripción completa

Detalles Bibliográficos
Autores principales: Korfei, Martina, Stelmaszek, Daniel, MacKenzie, BreAnne, Skwarna, Sylwia, Chillappagari, Shashipavan, Bach, Anna C., Ruppert, Clemens, Saito, Shigeki, Mahavadi, Poornima, Klepetko, Walter, Fink, Ludger, Seeger, Werner, Lasky, Joseph A., Pullamsetti, Soni S., Krämer, Oliver H., Guenther, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258535/
https://www.ncbi.nlm.nih.gov/pubmed/30481203
http://dx.doi.org/10.1371/journal.pone.0207915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258535/
https://www.ncbi.nlm.nih.gov/pubmed/30481203
http://dx.doi.org/10.1371/journal.pone.0207915

Ejemplares similares